Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2019 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.6%

Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock still declined by 0.6%, indicating that investors may be concerned about the lack of revenue details and future guidance. The cautious tone from management may have also contributed to the stock's reaction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.50	N/A	+21.89%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their product pipeline. They emphasized the importance of upcoming trials and developments.

Management highlighted ongoing progress in their pipeline.

They expressed confidence in future developments despite current losses.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.6%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.6%

Key numbers

Management commentary